Effects of gamma-oryzanol on serum lipids and apolipoproteins in dyslipidemic schizophrenics receiving major tranquilizers

Clin Ther. May-Jun 1990;12(3):263-8.

Abstract

The subjects were 20 chronic schizophrenic patients with dyslipidemia (total cholesterol levels greater than or equal to 220 mg/dl, triglycerides greater than or equal to 150 mg/dl, or high-density lipoprotein cholesterol less than or equal to 40 mg/dl) who had been receiving neuroleptics for a mean of ten years. Each patient was given 100 mg of gamma-oryzanol three times daily for 16 weeks. Total cholesterol and low-density lipoprotein cholesterol levels, respectively, decreased significantly, from 204 and 124 mg/dl at baseline to 176 and 101 mg/dl at week 12. High-density lipoprotein cholesterol levels were 36.1 mg/dl at baseline and 35.9 mg/dl at week 12. Apolipoprotein (apo) B levels decreased significantly from 116 mg/dl to 101 mg/dl at week 16; apo A-II levels increased significantly from 31.7 mg/dl to 34.7 mg/dl; and the apo B/apo A-I ratio declined significantly from 0.99 to 0.84. No treatment side effects were recorded. It is concluded that gamma-oryzanol is safe and effective in the treatment of dyslipidemia.

MeSH terms

  • Antipsychotic Agents / adverse effects
  • Antipsychotic Agents / therapeutic use*
  • Apolipoproteins / blood*
  • Body Weight / drug effects
  • Cholesterol, HDL / blood
  • Cholesterol, LDL / blood
  • Chronic Disease
  • Female
  • Humans
  • Hypolipidemic Agents / therapeutic use*
  • Lipids / blood*
  • Male
  • Middle Aged
  • Phenylpropionates / pharmacology*
  • Schizophrenia / blood*
  • Schizophrenia / complications
  • Schizophrenia / drug therapy

Substances

  • Antipsychotic Agents
  • Apolipoproteins
  • Cholesterol, HDL
  • Cholesterol, LDL
  • Hypolipidemic Agents
  • Lipids
  • Phenylpropionates
  • gamma-oryzanol